Prognostic and Predictive Value of CCND1/Cyclin D1 Amplification in Breast Cancer With a Focus on Postmenopausal Patients: A Systematic Review and Meta-Analysis

BACKGROUND: Up to 80% of breast cancers (BCa) are estrogen receptor positive and current treatments target the estrogen receptor (endocrine therapies) and/or CDK4/6 (CDK4/6 inhibitors). CCND1 encodes the protein cyclin D1, responsible for regulation of G1 to S phase transition in the cell cycle. CCN...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeffreys, Sarah A., Becker, Therese M., Khan, Sarah, Soon, Patsy, Neubauer, Hans, de Souza, Paul, Powter, Branka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9249016/
https://www.ncbi.nlm.nih.gov/pubmed/35784572
http://dx.doi.org/10.3389/fendo.2022.895729

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9249016/
https://www.ncbi.nlm.nih.gov/pubmed/35784572
http://dx.doi.org/10.3389/fendo.2022.895729

Ejemplares similares